遗传性额颞叶痴呆生存估计及预测因素:国际回顾性队列研究
该国际回顾性队列研究基于GENFI队列278例携带C9orf72、GRN或MAPT致病突变的遗传性额颞叶痴呆患者,采用Kaplan-Meier法评估生存并分析预测因素。起病年龄较大、入组时病程较短、额颞叶痴呆-肌萎缩侧索硬化临床表型、运动或语言起病及居住于中欧和南欧与较差预后相关。
要点
- 基因型不直接影响生存,其效应由起病年龄和临床表型介导。
- 运动障碍合并认知行为症状时应纳入预后评估。
核心结论
- 基因型不直接影响生存,其效应由起病年龄和临床表型介导。
- 运动障碍合并认知行为症状应纳入预后评估,个体化风险评分有助于未来治疗试验分层。
研究设计与样本
- 国际回顾性队列研究,纳入GENFI队列32个研究站点278例携带C9orf72扩增或GRN、MAPT致病突变的患者。
- 采用Kaplan-Meier法评估生存,Cox比例风险模型识别预测因素并在独立队列外部验证。
- 进一步构建结构方程模型评估预测因素间关系,应用LASSO方法。
- 生存时间定义为从症状起病至死亡或删失日期,所有患者中位生存估计为主要终点。
主要发现
- 278例中160例(58%)为男性,118例(42%)为女性;162例(58%)随访期间死亡,116例(42%)至2024年6月1日删失时仍存活。
- 138例携带C9orf72扩增,94例携带GRN突变,46例携带MAPT突变。
- 179例诊断为行为变异型额颞叶痴呆,46例为原发性进行性失语,31例为额颞叶痴呆-肌萎缩侧索硬化,22例为其他诊断。
- 起病年龄较大、入组时病程较短、额颞叶痴呆-肌萎缩侧索硬化表型、运动或语言起病及居住于中欧和南欧与较差预后相关。
关键数值与推荐
- 基因型不直接影响生存,其效应由起病年龄和临床表型介导。
临床怎么用
- 估算遗传性额颞叶痴呆预后时,除认知和行为症状外,应同时考虑运动障碍。
- 可依据起病年龄、临床表型、起病症状域和地理区域等预测因素进行个体化风险评估。
- 研究所构建的生存风险指数可用于个体患者层面,但需进一步细化和前瞻性验证。
- 个体风险评分可能有助于未来治疗试验中的患者分层。
局限性
- 本研究为回顾性队列研究。
- 生存风险指数需进一步细化和前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: What drives the heterogeneity of survival estimates in genetic frontotemporal dementia is unknown. We sought to understand the natural history and predictors of disease trajectory, which are crucial not only for effective care but also for the design of therapeutic clinical trials and efficacy evaluation. METHODS: In this international, cohort study, we used the Kaplan-Meier method to retrospectively assess survival estimates in patients enrolled in the GENFI cohort, which included 32 research sites located in Belgium, Canada, Finland, France, Germany, Italy, the Netherlands, Portugal, Spain, Sweden, and the UK, and comprised participants carrying a causal C9orf72 expansion or a causal mutation in GRN or MAPT genes. Survival was calculated as the time from symptom onset to time of death or censoring date; median survival estimate for all patients was the primary endpoint. Cox proportional hazards models were used to identify predictors of survival, which were subsequently externally validated in an independent cohort. We further designed a structural equation model to assess the relationships between predictors, applying a least absolute shrinkage and selection operator method. FINDINGS: Of 278 participants of the GENFI cohort included in this study, 160 (58%) were men and 118 (42%) were women. 162 died during follow-up (58%) and 116 were still alive (42%) on June 1, 2024, the chosen censoring date. 138 participants carried a C9orf72 expansion, 94 carried a GRN mutation, and 46 a MAPT mutation. 179 participants were diagnosed with behavioural variant frontotemporal dementia, 46 with primary progressive aphasia, and 31 with frontotemporal dementia-amyotrophic lateral sclerosis. 22 participants had other diagnoses. The median survival estimate for all patients with genetic frontotemporal dementia was 6·94 years (95% CI 6·59-7·80) from symptom onset. The median survival estimate for patients with GRN mutations was 6·63 years (6·08-7·98), for patients with a C9orf72 expansion was 7·04 years (6·45-8·77), and for patients with MAPT mutations was 8·56 years (7·06-13·50). Older age at onset, shorter disease duration from onset to enrolment in the GENFI study, clinical presentation (ie, frontotemporal dementia-amyotrophic lateral sclerosis), domain of first symptom (ie, motor or language onset), and geographical area of residency (ie, central and southern Europe) were associated with poorer prognosis. Genetic group did not directly affect survival estimates; rather its effect was mediated by age at onset and clinical phenotype. We computed a genetic frontotemporal dementia survival risk index, which can be used at an individual patient level. INTERPRETATION: Our results highlight that motor impairment in addition to cognitive and behavioural symptoms should be considered when estimating prognosis in genetic frontotemporal dementia. Individual risk scores might be of help for patient stratification in future therapeutic trials, although refinement and prospective validation are now needed. FUNDING: Italian Ministry of Health (Ricerca Corrente), Fondation Philippe Chatrier, and Fondation Vaincre Alzheimer.
引用
- Bouzigues A, Grassi M, Cantoni V, et al. Survival estimates and their predictors in genetic frontotemporal dementia: an international, retrospective, cohort study. Lancet Neurol. 2026. PMID: 42456683. doi:10.1016/S1474-4422(26)00197-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。